About 2-acylglycerol O-acyltransferase 3
2-acylglycerol O-acyltransferase 3 (MOGAT3) is a protein
from Homo sapiens identified by UniProt accession
Q86VF5, 341 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | 2-acylglycerol O-acyltransferase 3 |
|---|
| UniProt accession | Q86VF5 |
|---|
| Gene | MOGAT3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 341 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (10)
Diseases linked to this target (Open Targets).
- metabolite measurement · score 0.18
- serum metabolite measurement · score 0.16
- Barrett's esophagus · score 0.07
- hemoglobin measurement · score 0.05
- esophageal adenocarcinoma · score 0.04
- breast carcinoma · score 0.04
- Crohn's disease · score 0.01
- colorectal cancer · score 0.01
- non-alcoholic fatty liver disease · score 0.00
- Disorder of lipid metabolism · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86VF5-F1 | alphafold | PREDICTED | 92.91 | — |
Amino-acid sequence (341 residues)
MGVATTLQPP TTSKTLQKQH LEAVGAYQYV LTFLFMGPFF SLLVFVLLFT SLWPFSVFYL VWLYVDWDTP NQGGRRSEWI RNRAIWRQLR DYYPVKLVKT AELPPDRNYV LGAHPHGIMC TGFLCNFSTE SNGFSQLFPG LRPWLAVLAG LFYLPVYRDY IMSFGLCPVS RQSLDFILSQ PQLGQAVVIM VGGAHEALYS VPGEHCLTLQ KRKGFVRLAL RHGASLVPVY SFGENDIFRL KAFATGSWQH WCQLTFKKLM GFSPCIFWGR GLFSATSWGL LPFAVPITTV VGRPIPVPQR LHPTEEEVNH YHALYMTALE QLFEEHKESC GVPASTCLTF I
Explore 2-acylglycerol O-acyltransferase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets